Skip to main content
S&P 5007,541.40-0.51%DOW51,983.98+0.41%NASDAQ25,164.36-1.07%BTC$77,089.00-1.77%ETH$2,256.24-1.56%GOLD$3,959.60-0.25%OIL$96.57+0.11%
Smart Investors Daily
SID Premium
Instil Bio, Inc. logo

NASDAQ · TIL

Instil Bio, Inc.

Healthcare · Biotechnology

$6.80

Down-$0.25 (-3.68%)

Updated Nov 3, 2026, 1:51 AM

SID Score

2.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
75.08M
P/E ratio
-0.86
Dividend yield
0.00%
52-week range
$5.56 – $18.20
Volume
25.23K
Avg. volume
102.72K

Price performance · TIL

TIL price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

TIL closed at $6.80 after 20 trading sessions, down 2.16% for the selected period.

Last close
$6.80
Period change
-2.16%
Period low
$5.57
Period high
$6.95
Daily close
View OHLC price history
TIL OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$6.74$6.87$6.51$6.8025.23K
Oct 29, 2026$6.71$7.12$6.71$6.82557.66K
Oct 28, 2026$5.85$6.93$5.85$6.79149.61K
Oct 27, 2026$5.56$6.08$5.56$5.84102.05K
Oct 26, 2026$5.86$5.88$5.57$5.5736.69K
Oct 23, 2026$5.76$5.90$5.66$5.84121.35K
Oct 22, 2026$5.80$5.94$5.68$5.7084.88K
Oct 21, 2026$6.01$6.09$5.73$5.7740.87K
Oct 20, 2026$5.88$6.19$5.85$5.94100.16K
Oct 19, 2026$5.89$6.35$5.62$5.79147.9K
Oct 16, 2026$6.18$6.45$5.91$5.9125.17K
Oct 15, 2026$6.08$6.495$6.08$6.1333.02K
Oct 14, 2026$6.06$6.22$5.93$5.9544.12K
Oct 13, 2026$6.6107$6.6107$6.025$6.1827.61K
Oct 12, 2026$6.65$6.66$6.51$6.5811.33K
Oct 9, 2026$6.69$6.76$6.53$6.7437.62K
Oct 8, 2026$6.84$6.895$6.41$6.5654.5K
Oct 7, 2026$6.89$7.00$6.85$6.907.27K
Oct 6, 2026$7.2199$7.2199$6.82$6.88524.19K
Oct 5, 2026$7.22$7.35$6.95$6.9512.94K

Latest TIL news

The latest Smart Investors Daily articles mentioning TIL.

Stock researchCompany · Overview

TIL research

Overview

Company profile and research snapshot.

Company profile

Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$78.25
Implied upside
—
Analysts
—
TIL recent ratings
DateFirmRatingTarget
Jan 7, 2026HC Wainwright & Co.Neutral—
Sep 11, 2025HC Wainwright & Co.Buy—
Aug 27, 2025HC Wainwright & Co.Buy—
Aug 15, 2025HC Wainwright & Co.Buy—
Jun 5, 2025HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Jan 6, 2026

Instil Bio’s Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco

DALLAS, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL) (“Instil”) today announced that Axion Bio, Inc. (“Axion”), a wholly-owned subsidiary of Instil, has decided to discontinue clinical development of AXN-2510 and that Axion and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX: 1541.HK) (“ImmuneOnco”) have entered into an agreement terminating their license and collaboration agreement for AXN-2510 and AXN-27M (“Termination Agreement”). Under the terms of the Termination Agr

globenewswire.com · Nov 13, 2025

Instil Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update

DALLAS, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its third quarter 2025 financial results and provided a corporate update. Recent Highlights: In September, ImmuneOnco, Instil's collaborator, presented updated data from additional patients with relapsed/refractory squamous non-small cell lung cancer treated with ‘2510 as monotherapy in a poster presentation at the 2025 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By